Pharsight

Rocklatan patents expiration

ROCKLATAN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9096569 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(2 years from now)

US8450344 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(2 years from now)

US10654844 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(5 years from now)

US10174017 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(5 years from now)

US8394826 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Nov, 2030

(6 years from now)

US9993470 AERIE PHARMS INC Combination therapy
Mar, 2034

(9 years from now)

US9931336 AERIE PHARMS INC Combination therapy
Mar, 2034

(9 years from now)

US10588901 AERIE PHARMS INC Combination therapy
Mar, 2034

(9 years from now)

US9415043 AERIE PHARMS INC Combination therapy
Mar, 2034

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11021456 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(2 years from now)

US10882840 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(2 years from now)

US10532993 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(2 years from now)

US11028081 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(5 years from now)

US11618748 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(5 years from now)

US11185538 AERIE PHARMS INC Compositions for treating glaucoma or reducing intraocular pressure
Mar, 2034

(9 years from now)

US11197853 AERIE PHARMS INC Combination therapy
Mar, 2034

(9 years from now)

Rocklatan is owned by Aerie Pharms Inc.

Rocklatan contains Latanoprost; Netarsudil Dimesylate.

Rocklatan has a total of 16 drug patents out of which 0 drug patents have expired.

Rocklatan was authorised for market use on 12 March, 2019.

Rocklatan is available in solution/drops;ophthalmic dosage forms.

Rocklatan can be used as reduction of elevated intraocular pressure.

Drug patent challenges can be filed against Rocklatan from 2021-12-18.

The generics of Rocklatan are possible to be released after 14 March, 2034.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2022
New Combination (NC) Mar 12, 2022

Drugs and Companies using LATANOPROST; NETARSUDIL DIMESYLATE ingredient

NCE-1 date: 2021-12-18

Market Authorisation Date: 12 March, 2019

Treatment: Reduction of elevated intraocular pressure

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ROCKLATAN before it's drug patent expiration?
More Information on Dosage

ROCKLATAN family patents

Family Patents